Poseida Therapeutics Inc.

09/16/2024 | Press release | Distributed by Public on 09/16/2024 06:29

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P BCMA ALLO1 to Treat Relapsed/Refractory Multiple Myeloma

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.